Fintel reports that on September 30, 2024, Goldman Sachs initiated coverage of Celldex Therapeutics (NasdaqCM:CLDX) with a Neutral recommendation.
Analyst Price Forecast Suggests 101.12% Upside
As of September 25, 2024, the average one-year price target for Celldex Therapeutics is $68.34/share. The forecasts range from a low of $37.37 to a high of $94.50. The average price target represents an increase of 101.12% from its latest reported closing price of $33.98 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Celldex Therapeutics is 2MM, a decrease of 81.57%. The projected annual non-GAAP EPS is -2.71.
What is the Fund Sentiment?
There are 426 funds or institutions reporting positions in Celldex Therapeutics. This is an decrease of 15 owner(s) or 3.40% in the last quarter. Average portfolio weight of all funds dedicated to CLDX is 0.21%, an increase of 5.64%. Total shares owned by institutions increased in the last three months by 3.03% to 76,918K shares. 
The put/call ratio of CLDX is 0.51, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 8,076K shares representing 12.18% ownership of the company. In its prior filing, the firm reported owning 7,647K shares , representing an increase of 5.31%. The firm decreased its portfolio allocation in CLDX by 86.78% over the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 3,808K shares representing 5.74% ownership of the company. In its prior filing, the firm reported owning 3,369K shares , representing an increase of 11.51%. The firm increased its portfolio allocation in CLDX by 7.75% over the last quarter.
Kynam Capital Management holds 3,389K shares representing 5.11% ownership of the company. In its prior filing, the firm reported owning 2,900K shares , representing an increase of 14.43%. The firm decreased its portfolio allocation in CLDX by 24.05% over the last quarter.
Eventide Asset Management holds 3,327K shares representing 5.02% ownership of the company. In its prior filing, the firm reported owning 3,119K shares , representing an increase of 6.25%. The firm increased its portfolio allocation in CLDX by 2.68% over the last quarter.
Price T Rowe Associates holds 3,172K shares representing 4.79% ownership of the company. In its prior filing, the firm reported owning 3,087K shares , representing an increase of 2.69%. The firm decreased its portfolio allocation in CLDX by 11.53% over the last quarter.
Celldex Therapeutics Background Information
(This description is provided by the company.)
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly effect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
